449758-24-1

Usage

Uses

Used in Pharmaceutical Industry:
2-(1H-TETRAZOL-1-YL)BENZAMIDE is used as a potential antihypertensive agent for its ability to block the angiotensin II type 1 receptor, which plays a crucial role in regulating blood pressure.
Used in Cardiovascular Research:
TTB is used as a research compound for its potential role in treating cardiovascular diseases and hypertension, given its pharmacological properties that may help manage these conditions.
Used in Cancer Research:
2-(1H-TETRAZOL-1-YL)BENZAMIDE is used as an antitumor agent in cancer research, where it is being evaluated for its potential to combat cancer cells and contribute to cancer treatment strategies.
Used in Antifungal Research:
TTB is used as an antifungal agent in research settings, where its potential to inhibit fungal growth and treat fungal infections is being investigated.

Upstream product

• 116570-12-8 2-Tetrazol-1-yl-benzoic acid 
• 118-92-3 anthranilic acid 

Downstream Products

• 449758-25-2 2-Tetrazol-1-yl-benzonitrile 
• 449758-33-2 {(R)-1-Benzyl-2-oxo-2-[(S)-2-(2-tetrazol-1-yl-benzylcarbamoyl)-pyrrolidin-1-yl]-ethyl}-carbamic acid tert-butyl ester 
• 449756-94-9 2-Tetrazol-1-yl-benzylamine 

Relevant academic research and scientific papers

The impact of binding site waters on the activity/selectivity trade-off of Janus kinase 2 (JAK2) inhibitors

Structure based optimization of B39, an indazole-based low micromolar JAK2 virtual screening hit is reported. Analysing the effect of certain modifications on the activity and selectivity of the analogues suggested that these parameters are influenced by

1,6 - SUBSTITUTED (3R,6R) -3- (2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS

The present invention relates to compound S of Formula (I).

Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors

In an effort to discover potent, clinically useful thrombin inhibitors, a rapid analogue synthetic approach was used to explore the P1 region. Various benzylamines were coupled to a pyridine/pyrazinone P2-P 3 template. One compound with an o-thiadiazole benzylic substitution was found to have a thrombin Ki of 0.84 nM. A study of ortho-substituted five-membered-ring heterocycles was undertaken and subsequently demonstrated that the o-triazole and tetrazole rings were optimal. Combination of these potent P1 aryl heterocycles with a variety of P2-P3 groups produced a compound with an extraordinary thrombin inhibitory activity of 1.4 pM. It is hoped that this potency enhancement in P1 will allow for more diversification in the P 2-P3 region to ultimately address additional pharmacological concerns.